Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
P16 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Novel Immunotherapeutics (Translational)
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
P16.07 - Immuno-Modulatory Effects of Ceralasertib in Combination with Durvalumab in NSCLC with Progression on Anti-PD(L)1 Treatment (HUDSON)
00:00 - 00:00 | Presenter: Benjamin Besse
- Abstract
Loading...
-
+
OA01 - Established Drugs in Special Populations and New Drugs in Established Populations
- 09:15 - 10:15
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Immunotherapy (Phase II/III Trials)
-
+
OA01.03 - Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
09:15 - 09:25 | Presenter: Saadettin Kilickap
- Abstract
Loading...
-
+
ES02 - Pro-Con: Do We Need Biomarkers to Guide the Choice of Immunotherapy Treatment?
- 10:30 - 11:30
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Immunotherapy (Phase II/III Trials)
-
+
ES02.02 - Immune Checkpoint Blockade for All NSCLC Regardless of PD-L1, TMB or Other Biomarkers
10:45 - 11:00 | Presenter: Naiyer Rizvi
- Abstract
No abstract available for this presentation
-
+
OA07 - Immuno-biology and Novel Immunotherapeutics from Bench to Bed
- 10:30 - 11:30
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
OA07.08 - HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy
11:05 - 11:10 | Presenter: Benjamin Besse
- Abstract
Loading...
